Oncotarget

Research Papers:

Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372

Yawei Wang, Ye Hu, Gang Wu _, Ye Yang, Yanqing Tang, Wanchuan Zhang, Kaiyu Wang, Yu Liu, Xin Wang and Tiemin Li

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:34429-34441. https://doi.org/10.18632/oncotarget.16260

Metrics: PDF 1538 views  |   HTML 2003 views  |   ?  


Abstract

Yawei Wang1, Ye Hu2, Gang Wu3, Ye Yang1, Yanqing Tang4, Wanchuan Zhang3, Kaiyu Wang3, Yu Liu1, Xin Wang1, Tiemin Li1

1Department of Geriatric Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China

2Department of Nephrology, Liaoning Provincial People’s Hospital, Shenyang, Liaoning 110000, China

3Department of General Surgery, The First Hospital Affiliated to China Medical University, Shenyang, Liaoning 110001, China

4Department of Psychology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China

Correspondence to:

Gang Wu, email: 18660232387@163.com

Keywords: PCAT-14, miR-372, HCC, proliferation, invasion

Received: November 30, 2016     Accepted: March 08, 2017     Published: March 16, 2017

ABSTRACT

Long non-coding RNAs (lncRNAs) regulate oncogenesis by inducing methylation of CpG islands to silence target genes. Here we show that the lncRNA PCAT-14 is overexpressed in patients with hepatocellular carcinoma (HCC), and is associated with a poor prognosis after surgery. Our results demonstrate that PCAT-14 promotes proliferation, invasion, and cell cycle arrest in HCC cells. In addition, PCAT-14 inhibits miR-372 expression by inducing methylation of the miR-372 promoter. Simultaneously, miR-372 eliminates the effects of PCAT-14 on proliferation, invasion, and cell cycle in HCC cells. Moreover, PCAT-14 regulates expression of ATAD2 and activation of the Hedgehog pathway via miR-372. These findings indicate that PCAT-14 plays an important role in HCC, and may serve as a novel prognostic factor and therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16260